|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-11-8
|
|
pubmed:abstractText |
The c-kit receptor is expressed in 95% of relapsed acute myeloid leukemias (AMLs) and mediates leukemic proliferation. We conducted a Phase 1 study of the c-kit inhibitor, imatinib mesylate (IM), in combination with cytarabine and daunorubicin (7+3) in c-kit+ relapsed AML. IM was dose escalated using a 3 by 3 design. Phosphorylated STAT5 was absent to minimally present in residual blasts on day 14 bone marrows. The maximum tolerated dose of IM was 300 mg. The dose-limiting toxicity was Grade 3-4 hepatic toxicity. The CR/CRp rate was 57%. Cytotoxic therapy that includes IM for relapsed AML is well-tolerated and effective.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1873-5835
|
|
pubmed:author |
pubmed-author:AdvaniAnjali SAS,
pubmed-author:BatesJenniferJ,
pubmed-author:CopelanEdward AEA,
pubmed-author:CottaClaudiu VCV,
pubmed-author:EgorinMerrill JMJ,
pubmed-author:HowardMatthewM,
pubmed-author:HsiEricE,
pubmed-author:KalaycioMattM,
pubmed-author:LEVILa LLL,
pubmed-author:LimKathleenK,
pubmed-author:MaciejewskiJaroslawJ,
pubmed-author:NoonElysaE,
pubmed-author:PriceCourtneyC,
pubmed-author:RushMary LynnML,
pubmed-author:SalvadoAugustA,
pubmed-author:SaunthararajahYogenY,
pubmed-author:SekeresMikkael AMA,
pubmed-author:SobecksRonaldR,
pubmed-author:TiuRamonR,
pubmed-author:TrippBarbaraB
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1622-6
|
|
pubmed:meshHeading |
pubmed-meshheading:20427086-Adult,
pubmed-meshheading:20427086-Aged,
pubmed-meshheading:20427086-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20427086-Cytarabine,
pubmed-meshheading:20427086-Daunorubicin,
pubmed-meshheading:20427086-Female,
pubmed-meshheading:20427086-Humans,
pubmed-meshheading:20427086-Leukemia, Myeloid, Acute,
pubmed-meshheading:20427086-Male,
pubmed-meshheading:20427086-Maximum Tolerated Dose,
pubmed-meshheading:20427086-Middle Aged,
pubmed-meshheading:20427086-Phosphorylation,
pubmed-meshheading:20427086-Piperazines,
pubmed-meshheading:20427086-Proto-Oncogene Proteins c-kit,
pubmed-meshheading:20427086-Pyrimidines,
pubmed-meshheading:20427086-Recurrence,
pubmed-meshheading:20427086-STAT5 Transcription Factor
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
|
|
pubmed:affiliation |
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA. advania@ccf.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
